Shopping Cart

Your shopping cart is currently empty

Carglumic Acid

Name: Carglumic Acid
Brand: TargetMol
SKU: T0755
Price: 48 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0755Cas No. 1188-38-1

Alias Ureidoglutaric acid, N-Carbamyl-L-glutamic acid, N-Carbamylglutamate, Carbamylglutamic acid, Carbamino-L-glutamic acid, Carbaglu

Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010.

Carglumic Acid

Copy Product Info

😃Good

Purity: 99.54%

Catalog No. T0755Alias Ureidoglutaric acid, N-Carbamyl-L-glutamic acid, N-Carbamylglutamate, Carbamylglutamic acid, Carbamino-L-glutamic acid, CarbagluCas No. 1188-38-1

Pack Size	Price	USA Warehouse	Global Warehouse
200 mg	$48	In Stock	-
500 mg	$89	Inquiry	Inquiry
1 g	$119	Inquiry	Inquiry
1 mL x 10 mM (in DMSO)	$55	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.54%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR

Product Introduction

Carglumic Acid AI Summary

Carglumic Acid exhibits diverse bioactivities, demonstrating potential antiviral properties against both the Ebola virus and SARS-CoV-2. Against the Ebola virus, the compound has shown potency in inhibiting viral entry with IC50 values ranging from 631.0 nM to 5011.9 nM. For SARS-CoV-2, Carglumic Acid inhibits cytotoxicity in Caco-2 cells by 7.18% at a 10 µM concentration after 48 hours, and demonstrates some activity in HRCE cells against the USA-WA1/2020 strain with a hit score of 0.1387. Furthermore, it shows 3CL-Pro protease inhibition with varying activities, including -4.06% to 8.602% inhibition at a 20 µM concentration. However, the compound exhibits an average inhibition rate of -0.05% in VERO-6 cells at 10 µM after 48 hours of exposure to the virus. Additionally, Carglumic Acid appears to interact with the human HDAC6 enzyme, showing 9.69% inhibition in one enzymatic assay, though another assay revealed an inhibition of -5.56%. Despite demonstrating affinity and some agonist/antagonist activities towards various receptors and transporters, the low binding affinity with AC50 values greater than 30000.0 nM suggests limited significance at the tested targets..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Carglumic Acid (Ureidoglutaric acid) is an orphan drug used to treat hyperammonemia in patients with N-acetyl glutamate synthase absence. This rare hereditary disease results in elevated blood levels of ammonia, which can eventually cross the blood-brain barrier and lead to neurologic problems, coma, cerebral edema, and death. Carglumic acid was approved by the U.S. FDA on 18 March 2010.
Synonyms	Ureidoglutaric acid, N-Carbamyl-L-glutamic acid, N-Carbamylglutamate, Carbamylglutamic acid, Carbamino-L-glutamic acid, Carbaglu

Chemical Properties

Molecular Weight	190.15
Formula	C₆H₁₀N₂O₅
Cas No.	1188-38-1
Smiles	[C@@H](CCC(O)=O)(NC(N)=O)C(O)=O
Relative Density.	1.499g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 125 mg/mL (657.38 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (10.52 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	5.2590 mL	26.2950 mL	52.5901 mL	262.9503 mL
5 mM	1.0518 mL	5.2590 mL	10.5180 mL	52.5901 mL
10 mM	0.5259 mL	2.6295 mL	5.2590 mL	26.2950 mL
20 mM	0.2630 mL	1.3148 mL	2.6295 mL	13.1475 mL
50 mM	0.1052 mL	0.5259 mL	1.0518 mL	5.2590 mL
100 mM	0.0526 mL	0.2630 mL	0.5259 mL	2.6295 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc